Natalie Arnold/LinkedIn
Jan 25, 2026, 12:17
Natalie Arnold on 11 Clinical Trials That Will Shape Medicine in 2026
Natalie Arnold, Preventive Cardiologist at University Heart and Vascular Center Hamburg, shared on LinkedIn:
”“What does the coming day hold (for me)?”
(AS Pushkin, Eugene Onegin)
Nature Medicine recently spotlighted 11 clinical trials that may shape medicine in 2026.
Two of them align directly with my research focus in cardiovascular prevention:
• Low-grade inflammation: IL-6 inhibition with ziltivekimab
• Lipoprotein (a): pelacarsen for patients with elevated Lp(a)
2026 may be a key year for turning “residual risk” biology into therapies that improve clinical outcomes.”
Read the full article here.
Article: Eleven clinical trials that will shape medicine in 2026
Author: Mike May
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight
-
Aug 14, 2026, 18:20Venkata Sagi: Systemic Anticoagulation or Left Atrial Appendage Closure?
-
Aug 14, 2026, 18:02Marios Psychogios: Every Minute Matters in Acute Stroke Care
-
Aug 14, 2026, 17:57Molly Lippold-Meinholz: The Magic of Camp for Kids With Bleeding Disorders
-
Aug 14, 2026, 17:52Will Thomas: Why Dose Every Missed Thromboprophylaxis Matter
-
Aug 14, 2026, 17:42Nandini Pethe: Representing MicroHealth at BDC
-
Aug 14, 2026, 17:30Richard Habis: Hemophilia Does Not Only Affect the Child
-
Aug 14, 2026, 17:00Zahra Safarzadeh: The Critical Role of the Laboratory in Hemophilia Care
-
Aug 14, 2026, 16:39Yuriy Prokopenko: Advancing Hemostasis Through Scientific Collaboration